A new analysis argues that breakthrough biotherapies still face a major hidden hurdle: whether companies have the operational talent and quality systems to move assets through GMP manufacturing, regulatory review, supply chain setup, and commercialization. The piece emphasizes that expertise in QA/QC, validation, and regulated production can’t be built overnight, putting experienced teams and manufacturing ecosystems into sharper focus for investors.